Table 2.

Inhibition of the human isoforms hCA I and hCA II, and Entamoeba histolytica (EhiCA) from Entamoeba histolytica with sulfonamides 1–24 and the clinically used drugs AAZ–HCT, by a stopped-flow, CO₂ hydrase assay [35].

Inhibitor/Enzyme Class	KI * (nM)
	hCA I a	hCA II a	EhiCA
	α	α	β
1	28,000	300	2363
2	25,000	240	6011
3	79	8	951
4	78,500	320	833
5	25,000	170	567
6	21,000	160	798
7	8300	60	>10,000
8	9800	110	>10,000
9	6500	40	>10,000
10	7300	54	4656
11	5800	63	742
12	8400	75	1911
13	8600	60	821
14	9300	19	579
15	5500	80	772
16	9500	94	89
17	21,000	125	36
18	164	46	383
19	109	33	521
20	6	2	385
21	69	11	368
22	164	46	331
23	109	33	290
24	95	30	285
AAZ	250	12	509
MZA	50	14	845
EZA	25	8	746
DCP	1200	38	790
DZA	50,000	9	6444
BRZ	45,000	3	3051
BZA	15	9	2471
TPM	250	10	3100
ZNS	56	35	9595
SLP	1200	40	>10,000
IND	31	15	822
VLX	54,000	43	>10,000
CLX	50,000	21	>10,000
SLT	374	9	6727
SAC	18,540	5959	>10,000
HCT	328	290	3402

* Errors in the range of 5–10% of the reported data, from 3 different assays (data not shown). ^a Human recombinant isozymes, stopped flow CO₂ hydrase assay method, from References [11,12,13,14,15].